Kaken Pharmaceutical Co. Ltd. reported consolidated earnings results for the first quarter ended June 30, 2016. For the quarter, the company reported income before income taxes of JPY 8,187 million against JPY 9,346 million a year ago.

For the six months of fiscal year 2017, the company expects net sales of JPY 52,700 million, operating income of JPY 14,100 million, ordinary income of JPY 14,200 million and net income attributable to owners of parent was JPY 10,000 million or JPY 243.16 per share.

For the fiscal year 2017, the company expects net income attributable to owners of parent per share of JPY 505.78.

The company provides second quarter and year end dividend guidance for the fiscal year 2017. The company expects to pay second quarter and year end dividend of JPY 75 per share.